Healthcare
Chinese eye hospital chain Chaoju raises $59m
Chinese eye hospital chain operator Chaoju Ophthalmology has raised RMB400 million ($59 million) in a Series B round of funding backed by Orchid Asia Group and River Head Capital.
Ping An, CITIC invest China's Airdoc
Ping An Insurance and CITIC Group have made a Series B investment of undisclosed size in Airdoc, a Chinese medical services company that uses artificial intelligence (AI).
AVCJ Awards 2018: Exit of the Year - Mid Cap: Novotech
Mercury Capital secured a 15.7x return by helping Australian clinical trials specialist Novotech upgrade its marketing and personnel as well as pursue Asian expansion
US, China-based Apollomics raises $100m Series B
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
Chinese cancer database provider Medbanks raises $59m
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Sequoia, HighLight lead $80m round for China's BrightGene
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
China’s Zhiyun Health nets $100m Series C round
Chinese online healthcare services provider Zhiyun Health has raised $100 million in a Series C round of funding across two tranches.
AVCJ Awards 2018: PE & VC Professional of the Year: Sanjiv Kaul
Sanjiv Kaul, who left a career with pharma giant Ranbaxy to become an investor at ChrysCapital Partners, discusses the evolution of operational capabilities in Indian private equity
China's Miaoshou Doctor raises $72.8m
China-based healthcare care services provider Miaoshou Doctor has raised RMB500 million ($72.8 million) in an extended Series C round of funding led by Starquest Capital, with participation from Sequoia Capital China.
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
Chinese gene therapy player raises $45m
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.
Iron Pillar leads $22m round for India's Vyome Therapeutics
Indian venture capital firm Iron Pillar Capital Management has led a $22 million Series D round for Vyome Therapeutics, a domestic pharmaceuticals developer focused on skin diseases.
Advantech leads $55m round for China biotech player
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
China’s Antengene raises $120m Series B round
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
KKR to assume control of Indian hospital operator Max Healthcare
KKR-backed Radiant Life Care is taking majority control of Indian hospital operator Max Healthcare, three months after agreeing to buy a 49.7% stake held by South Africa’s Life Healthcare Group.
Brookfield nears $3.16b bid for Australia's Healthscope
Brookfield Asset Management expects to proceed with a A$4.49 billion ($3.16 billion) take-private offer for Australia-listed hospital operator Healthscope, although BGH Capital – which began its pursuit of the company eight months ago – has indicated...
Actis exits India's Symbiotec to MOPE, Invascent
Motilal Oswal Private Equity (MOPE) and healthcare-focused GP Invascent Capital have invested in Indian pharmaceutical developer Symbiotec Pharmalab, providing an exit for Actis Capital.
Fosun-owned Henlius Biotech files for Hong Kong IPO
Shanghai Henlius Biotech, a Chinese drug developer controlled by Fosun Group, has filed for a Hong Kong IPO. Third-party investors include Loyal Valley Capital and China International Capital Corporation (CICC).
China drug trading platform Yaoshibang raises $133m Series D
Chinese B2B pharmaceutical trading and education platform Yaoshibang has raised $133 million in a Series D round of funding led by Tiger Global Management, H Capital, and DCM.
Junshi Biosciences seeks up to $414m in HK offering
Shanghai Junshi Biosciences, a Chinese drug developer backed by Hillhouse Capital, is seeking to raise up to HK$3.2 billion ($414 million) through a Hong Kong IPO.
PE-backed WuXi Apptech trades flat on Hong Kong debut
PE-backed WuXi AppTec, a contract pharmaceutical R&D services provider, traded flat on its Hong Kong debut, following an IPO of HK$9.1 billion ($1.1) billion.
CX buys stake in India's Veeda Clinical Research
CX Partners has led a consortium of private equity investors to commit an undisclosed sum to Indian contract research organization Veeda Clinical Research.
True North backs Zydus' acquisition of Heinz India
True North has invested INR10 billion ($140 million) in Indian health products manufacturer Zydus Wellness to support its acquisition of Heinz India.
